Cargando…

HIV/AIDS Vaccines: 2018

Human immunodeficiency virus (HIV) has infected 76 million people and killed an estimated 35 million. During its 40‐year history, remarkable progress has been made on antiretroviral drugs. Progress toward a vaccine has also been made, although this has yet to deliver a licensed product. In 2007, I w...

Descripción completa

Detalles Bibliográficos
Autor principal: Robinson, Harriet L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282490/
https://www.ncbi.nlm.nih.gov/pubmed/30099743
http://dx.doi.org/10.1002/cpt.1208
_version_ 1783379005065396224
author Robinson, Harriet L.
author_facet Robinson, Harriet L.
author_sort Robinson, Harriet L.
collection PubMed
description Human immunodeficiency virus (HIV) has infected 76 million people and killed an estimated 35 million. During its 40‐year history, remarkable progress has been made on antiretroviral drugs. Progress toward a vaccine has also been made, although this has yet to deliver a licensed product. In 2007, I wrote a review, HIV AIDS Vaccines: 2007. This review, HIV AIDS Vaccines: 2018, focuses on the progress in the past 11 years. I begin with key challenges for the development of an AIDS vaccine and the lessons learned from the six completed efficacy trials, only one of which has met with some success.
format Online
Article
Text
id pubmed-6282490
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-62824902018-12-10 HIV/AIDS Vaccines: 2018 Robinson, Harriet L. Clin Pharmacol Ther Reviews Human immunodeficiency virus (HIV) has infected 76 million people and killed an estimated 35 million. During its 40‐year history, remarkable progress has been made on antiretroviral drugs. Progress toward a vaccine has also been made, although this has yet to deliver a licensed product. In 2007, I wrote a review, HIV AIDS Vaccines: 2007. This review, HIV AIDS Vaccines: 2018, focuses on the progress in the past 11 years. I begin with key challenges for the development of an AIDS vaccine and the lessons learned from the six completed efficacy trials, only one of which has met with some success. John Wiley and Sons Inc. 2018-10-09 2018-12 /pmc/articles/PMC6282490/ /pubmed/30099743 http://dx.doi.org/10.1002/cpt.1208 Text en © 2018 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Reviews
Robinson, Harriet L.
HIV/AIDS Vaccines: 2018
title HIV/AIDS Vaccines: 2018
title_full HIV/AIDS Vaccines: 2018
title_fullStr HIV/AIDS Vaccines: 2018
title_full_unstemmed HIV/AIDS Vaccines: 2018
title_short HIV/AIDS Vaccines: 2018
title_sort hiv/aids vaccines: 2018
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282490/
https://www.ncbi.nlm.nih.gov/pubmed/30099743
http://dx.doi.org/10.1002/cpt.1208
work_keys_str_mv AT robinsonharrietl hivaidsvaccines2018